CD8A and neoplasm: These studies demonstrated that mice treated with urelumab/nivolumab combination had increased T-cell IFN-γ expression, increased tumor CD8+ T-cell/T-regulatory cell ratios, and slowed colon cancer and gastric cancer tumor growth compared with untreated controls65.